J&J inks clin­i­cal tri­al deal with Stand Up To Can­cer, lat­est phar­ma to join can­cer non­prof­it study ef­forts

John­son & John­son’s new deal with a lead­ing can­cer or­ga­ni­za­tion aims to boost di­ver­si­ty in ear­ly phase clin­i­cal tri­als. The $5 mil­lion spon­sor­ship agree­ment be­tween Janssen and Stand Up To Can­cer (SU2C) will help fund four groups of re­searchers across the US work­ing to re­move bar­ri­ers to en­rolling more pa­tients, es­pe­cial­ly those in “med­ical­ly un­der­served” com­mu­ni­ties.

SU2C is cur­rent­ly tak­ing ap­pli­ca­tions for the re­search teams that will work with fed­er­al­ly qual­i­fied health cen­ters, clin­ics and lo­cal groups that are al­ready part­nered with the un­der­rep­re­sent­ed pop­u­la­tions. Team ap­pli­cants who get a sec­ond go-around and in­vi­ta­tion to sub­mit a full ap­pli­ca­tion will have un­til the end of Au­gust. Teams will be se­lect­ed in Sep­tem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER